[go: up one dir, main page]

MX2018009430A - Antagonistas del receptor st2l y metodos de uso. - Google Patents

Antagonistas del receptor st2l y metodos de uso.

Info

Publication number
MX2018009430A
MX2018009430A MX2018009430A MX2018009430A MX2018009430A MX 2018009430 A MX2018009430 A MX 2018009430A MX 2018009430 A MX2018009430 A MX 2018009430A MX 2018009430 A MX2018009430 A MX 2018009430A MX 2018009430 A MX2018009430 A MX 2018009430A
Authority
MX
Mexico
Prior art keywords
methods
antagonists
st2l
st2l antagonists
fragments
Prior art date
Application number
MX2018009430A
Other languages
English (en)
Inventor
Michael Naso
Jinquan Luo
Karen Duff
Sheng- Jiun WU
Catherine Healy
Roberta Lamb
Ravi Malaviya
Michael Pratta
Natalie Fursov
Mark Tornetta
John Wheeler
Leroy Hall
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2018009430A publication Critical patent/MX2018009430A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Catching Or Destruction (AREA)

Abstract

La presente invención se refiere a los antagonistas de ST2L, los polinucleótidos que codifican para los antagonistas o fragmentos de éstos, y los métodos de preparación y sus usos.
MX2018009430A 2012-04-30 2014-10-30 Antagonistas del receptor st2l y metodos de uso. MX2018009430A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261640407P 2012-04-30 2012-04-30
US201261640238P 2012-04-30 2012-04-30
US13/798,204 US9090694B2 (en) 2012-04-30 2013-03-13 ST2L antibody antagonists
US13/798,226 US9212227B2 (en) 2012-04-30 2013-03-13 ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions

Publications (1)

Publication Number Publication Date
MX2018009430A true MX2018009430A (es) 2020-09-02

Family

ID=49477497

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014013200A MX358134B (es) 2012-04-30 2013-04-29 Antagonistas del receptor st2l y metodos de uso.
MX2018009430A MX2018009430A (es) 2012-04-30 2014-10-30 Antagonistas del receptor st2l y metodos de uso.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014013200A MX358134B (es) 2012-04-30 2013-04-29 Antagonistas del receptor st2l y metodos de uso.

Country Status (37)

Country Link
US (4) US9090694B2 (es)
EP (2) EP3597219A1 (es)
JP (3) JP6283354B2 (es)
KR (2) KR102147140B1 (es)
CN (2) CN104411333B (es)
AR (1) AR090909A1 (es)
AU (2) AU2013256645B2 (es)
BR (1) BR112014027165A2 (es)
CA (1) CA2871948C (es)
CL (1) CL2014002955A1 (es)
CO (1) CO7240389A2 (es)
CR (1) CR20140488A (es)
CY (1) CY1122308T1 (es)
DK (1) DK2844292T3 (es)
EA (2) EA031047B1 (es)
EC (1) ECSP14025178A (es)
ES (1) ES2755094T3 (es)
HR (1) HRP20191884T1 (es)
HU (1) HUE045864T2 (es)
IL (2) IL235401B (es)
LT (1) LT2844292T (es)
MX (2) MX358134B (es)
MY (1) MY166062A (es)
NI (1) NI201400125A (es)
NZ (3) NZ702136A (es)
PE (1) PE20150641A1 (es)
PH (2) PH12014502435A1 (es)
PL (1) PL2844292T3 (es)
PT (1) PT2844292T (es)
RS (1) RS59511B1 (es)
SG (2) SG11201407028WA (es)
SI (1) SI2844292T1 (es)
SM (1) SMT201900639T1 (es)
TW (3) TWI700299B (es)
UA (1) UA118336C2 (es)
UY (1) UY34774A (es)
WO (1) WO2013165894A2 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20161542T1 (hr) * 2009-11-30 2016-12-30 Janssen Biotech, Inc. MUTIRANA Fc ANTITIJELA SA UKLONJENOM EFEKTORSKOM FUNKCIJOM
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
US9090694B2 (en) * 2012-04-30 2015-07-28 Janssen Biotech, Inc. ST2L antibody antagonists
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
EA034834B1 (ru) 2013-03-15 2020-03-26 Ридженерон Фармасьютикалз, Инк. Антагонисты il-33 и их применение
AU2015204674B2 (en) 2014-01-10 2020-09-03 Anaptysbio, Inc. Antibodies directed against interleukin-33 (IL-33)
WO2015164354A1 (en) 2014-04-21 2015-10-29 The Childen's Hospital Of Philadelphia Compositions and methods for treating cytokine-related disorders
AU2015280436A1 (en) * 2014-06-23 2017-02-02 Bionomics, Inc. Antibodies that bind LGR4
JP7231326B2 (ja) 2014-11-10 2023-03-01 ジェネンテック， インコーポレイテッド Ｉｌ－３３媒介性障害のための治療及び診断方法
US10093730B2 (en) 2014-11-10 2018-10-09 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
CA2978449A1 (en) * 2015-03-02 2016-09-09 180 Therapeutics Lp Method of treating a localized fibrotic disorder using an il-33 antagonist
EP3313887A2 (en) * 2015-06-26 2018-05-02 MAB Discovery GmbH Monoclonal anti-il-1racp antibodies
AU2017208099A1 (en) * 2016-01-14 2018-08-09 Anaptysbio, Inc. Inhibition of allergic reaction using an IL-33 inhibitor
EP3241845A1 (en) 2016-05-06 2017-11-08 MAB Discovery GmbH Humanized anti-il-1r3 antibodies
US20190225682A1 (en) * 2016-09-02 2019-07-25 180 Therapeutics Lp Method of treating localized fibrotic disorders using an il-33/tnf bispecific antibody
EP3506920A4 (en) * 2016-09-02 2020-05-27 180 Therapeutics LP METHOD FOR TREATING SYSTEMIC FIBROTIC DISEASES WITH A BISPECIFIC IL-33 / TNF ANTIBODY
JOP20190093A1 (ar) 2016-10-28 2019-04-25 Lilly Co Eli أجسام مضادة لـ il-33 واستخداماتها
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
MA47459A (fr) 2017-02-10 2019-12-18 Hoffmann La Roche Anticorps anti-tryptase, compositions les contenant et leurs utilisations
JP7205995B2 (ja) * 2017-03-29 2023-01-17 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 共刺激性ｔｎｆ受容体に対する二重特異性抗原結合分子
IL314591A (en) 2017-04-13 2024-09-01 Regeneron Pharma Treatment and prevention of inflammatory lung diseases in patients with risk alleles in the genes encoding IL33 and IL1RL1
EP3401332A1 (en) 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions
BR112020011469A2 (pt) 2017-12-21 2020-11-24 F. Hoffmann-La Roche Ag anticorpos, molécula de ligação ao antígeno biespecífica, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método para produzir um anticorpo, composição farmacêutica, uso do anticorpo, método de tratamento de uma doença e invenção
CN111787947A (zh) 2018-02-09 2020-10-16 豪夫迈·罗氏有限公司 用于肥大细胞介导的炎性疾病的治疗和诊断方法
IL277890B2 (en) 2018-04-11 2024-03-01 Regeneron Pharma Methods for quantifying il-33
US20210403579A1 (en) * 2018-10-31 2021-12-30 Delinia, Inc. Multivalent regulatory t cell modulators
KR102353568B1 (ko) 2018-11-14 2022-01-20 주식회사 헬릭스미스 안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편
CN110045131B (zh) * 2019-06-14 2019-09-03 迈威(上海)生物科技有限公司 用于测定人il-33/st2通路抑制剂的生物学活性的方法
CA3158366A1 (en) 2019-11-04 2021-05-14 Medimmune Limited Anti il-33 therapeutic agent fpr treating renal disorders
KR20220093334A (ko) 2019-11-04 2022-07-05 메디뮨 리미티드 Il-33 길항제의 이용 방법
WO2021180858A1 (en) 2020-03-13 2021-09-16 Medimmune Limited Therapeutic methods for the treatment of subjects with risk alelles in il33
EP4118114A1 (en) 2020-03-13 2023-01-18 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
AU2021253117B2 (en) 2020-04-06 2025-08-14 Medimmune Limited Treating acute respiratory distress syndrome with IL-33 axis binding antagonists
US20230272086A1 (en) * 2020-05-12 2023-08-31 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. St2 antigen binding protein
CN113501878B (zh) * 2021-02-03 2022-12-02 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
TW202304965A (zh) 2021-05-04 2023-02-01 美商艾吉納斯公司 抗ｔｉｇｉｔ抗體、抗ｃｄ９６抗體及其使用方法
TW202322850A (zh) * 2021-08-05 2023-06-16 美商美國禮來大藥廠 抗體最佳化
WO2023086807A1 (en) 2021-11-10 2023-05-19 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
JP2025508835A (ja) * 2022-02-24 2025-04-10 シノマブ バイオサイエンス リミテッド アラーミンに対する二重特異性結合タンパク質およびその使用
CN115838425B (zh) * 2022-08-31 2024-06-18 首都医科大学 一种靶向血管紧张素ii 1型受体细胞外第二环的抗体及其应用
TW202428613A (zh) 2022-09-21 2024-07-16 法商賽諾菲生物技術公司 人源化抗il-1r3抗體及使用方法
CN119841936B (zh) * 2024-12-30 2025-09-30 中国农业科学院兰州兽医研究所(中国动物卫生与流行病学中心兰州分中心) 抗非洲猪瘟病毒p72蛋白中和性单克隆抗体5d2及其应用

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
AU690528B2 (en) 1992-12-04 1998-04-30 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
EP0731842A1 (en) 1993-12-03 1996-09-18 Medical Research Council Recombinant binding proteins and peptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
WO1997014719A1 (en) 1995-10-16 1997-04-24 Unilever N.V. A bifunctional or bivalent antibody fragment analogue
WO1998015614A1 (en) 1996-10-10 1998-04-16 Life Technologies, Inc. Animal cell culture media comprising plant-derived nutrients
GB9727172D0 (en) 1997-12-24 1998-02-25 Univ Glasgow Reagents specific for st2l and uses therefor
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
GB9911569D0 (en) 1999-05-18 1999-07-21 Oxford Biomedica Ltd Antibodies
US6323334B1 (en) * 1999-09-24 2001-11-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding a 103 gene product and uses therefor
WO2001070817A1 (en) 2000-03-21 2001-09-27 Medical & Biological Laboratories Co., Ltd. Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same
ES2295228T3 (es) 2000-11-30 2008-04-16 Medarex, Inc. Roedores transcromosomicos transgenicos para la preparacion de anticuerpos humanos.
ES2727425T3 (es) * 2000-12-12 2019-10-16 Medimmune Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
US6649055B1 (en) 2002-05-07 2003-11-18 The United States Of America As Represented By The United States Department Of Energy Pump station for radioactive waste water
US8597911B2 (en) 2003-06-11 2013-12-03 Chugai Seiyaku Kabushiki Kaisha Process for producing antibodies
JP2007522118A (ja) * 2004-01-30 2007-08-09 ペプリン バイオリピッズ ピーティーワイ エルティーディー 治療用分子および担体分子
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
US20090060920A1 (en) 2004-11-15 2009-03-05 Eli Lilly And Company Desacyl ghrelin antibodies and therapeutic uses thereof
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
EP2035456A1 (en) 2006-06-22 2009-03-18 Novo Nordisk A/S Production of bispecific antibodies
US7560530B1 (en) 2006-07-20 2009-07-14 Schering Corporation IL-33 receptor
HRP20140081T1 (hr) 2006-08-18 2014-03-28 Novartis Ag Prlr-specifiäśna antitijela i njihova uporaba
WO2008119353A1 (en) 2007-03-29 2008-10-09 Genmab A/S Bispecific antibodies and methods for production thereof
US20100260770A1 (en) 2007-05-18 2010-10-14 Medimmune, Llc Il-33 in inflammatory disease
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
JP2011507519A (ja) 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
AU2009204501B2 (en) 2008-01-07 2015-02-12 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
BRPI0910482A2 (pt) 2008-04-29 2019-09-24 Abbott Lab imunoglobinas de domínio variável duplo e usos das mesmas
AU2010203712A1 (en) 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
US8817596B2 (en) 2009-01-09 2014-08-26 Futurewei Technologies, Inc. Protecting ingress and egress of a label switched path
US7879978B2 (en) 2009-03-31 2011-02-01 Centocor Ortho Biotech, Inc. Macaca fascicularis ST2L
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
HRP20161542T1 (hr) * 2009-11-30 2016-12-30 Janssen Biotech, Inc. MUTIRANA Fc ANTITIJELA SA UKLONJENOM EFEKTORSKOM FUNKCIJOM
US20110206672A1 (en) 2010-02-25 2011-08-25 Melvyn Little Antigen-Binding Molecule And Uses Thereof
HRP20180340T1 (hr) 2010-03-30 2018-03-23 Janssen Biotech, Inc. Humanizirana il-25 protutijela
RS54762B1 (sr) 2010-04-09 2016-10-31 Critical Care Diagnostics Inc Solubilna humana st-2 antitela i eseji
CN110066339A (zh) 2010-04-20 2019-07-30 根马布股份公司 含异二聚体抗体fc的蛋白及其制备方法
JP6022444B2 (ja) 2010-05-14 2016-11-09 ライナット ニューロサイエンス コーポレイション ヘテロ二量体タンパク質ならびにそれを生産および精製するための方法
EP2420253A1 (en) 2010-08-20 2012-02-22 Leadartis, S.L. Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
EP3050899B1 (en) 2010-09-27 2019-09-04 Janssen Biotech, Inc. Antibodies binding human collagen ii
HUE047228T2 (hu) 2010-11-05 2020-04-28 Zymeworks Inc Stabil heterodimer antitest-kialakítás az FC doménben mutációval
KR102003075B1 (ko) 2011-02-23 2019-07-23 에프. 호프만-라 로슈 아게 인간 il33r에 대한 항체 및 이의 용도
US9090694B2 (en) * 2012-04-30 2015-07-28 Janssen Biotech, Inc. ST2L antibody antagonists
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2

Also Published As

Publication number Publication date
NZ702136A (en) 2017-03-31
SG10201608525SA (en) 2016-12-29
US9951137B2 (en) 2018-04-24
CY1122308T1 (el) 2021-01-27
EP3597219A1 (en) 2020-01-22
MX2014013200A (es) 2014-12-08
TW201730216A (zh) 2017-09-01
US9212227B2 (en) 2015-12-15
JP2015516817A (ja) 2015-06-18
AU2017202610A1 (en) 2017-05-11
ES2755094T3 (es) 2020-04-21
IL254569A0 (en) 2017-11-30
HRP20191884T1 (hr) 2020-02-07
SG11201407028WA (en) 2015-01-29
SMT201900639T1 (it) 2020-01-14
PT2844292T (pt) 2019-11-26
UA118336C2 (uk) 2019-01-10
TWI700299B (zh) 2020-08-01
CN104411333B (zh) 2017-04-26
PL2844292T3 (pl) 2020-03-31
CA2871948A1 (en) 2013-11-07
AU2017202610B2 (en) 2019-06-13
DK2844292T3 (da) 2019-10-21
EA201891264A2 (ru) 2018-11-30
MY166062A (en) 2018-05-22
US9090694B2 (en) 2015-07-28
US20130336980A1 (en) 2013-12-19
MX358134B (es) 2018-08-06
PH12018501839A1 (en) 2020-09-14
WO2013165894A3 (en) 2014-03-27
PE20150641A1 (es) 2015-05-11
IL235401A0 (en) 2014-12-31
NZ729913A (en) 2018-07-27
EP2844292A4 (en) 2016-05-25
NZ740221A (en) 2019-11-29
IL235401B (en) 2020-10-29
JP2018064560A (ja) 2018-04-26
JP2019162136A (ja) 2019-09-26
EA031047B1 (ru) 2018-11-30
US20130287777A1 (en) 2013-10-31
JP6622274B2 (ja) 2019-12-18
KR20150008152A (ko) 2015-01-21
EP2844292B1 (en) 2019-08-21
UY34774A (es) 2013-11-29
NI201400125A (es) 2016-11-30
LT2844292T (lt) 2019-11-25
US20170066831A1 (en) 2017-03-09
TW202019969A (zh) 2020-06-01
CL2014002955A1 (es) 2015-01-16
EA201491996A1 (ru) 2015-04-30
CN104411333A (zh) 2015-03-11
US10450377B2 (en) 2019-10-22
CN107098973A (zh) 2017-08-29
TWI589588B (zh) 2017-07-01
JP6283354B2 (ja) 2018-02-21
IL254569B (en) 2020-10-29
HUE045864T2 (hu) 2020-01-28
PH12014502435A1 (en) 2015-01-12
HK1208182A1 (en) 2016-02-26
US20190062439A1 (en) 2019-02-28
CO7240389A2 (es) 2015-04-17
TWI687440B (zh) 2020-03-11
KR20200037886A (ko) 2020-04-09
RS59511B1 (sr) 2019-12-31
EP2844292A2 (en) 2015-03-11
EA201891264A3 (ru) 2019-02-28
KR102147140B1 (ko) 2020-08-25
AU2013256645B2 (en) 2017-06-08
AR090909A1 (es) 2014-12-17
BR112014027165A2 (pt) 2017-07-18
WO2013165894A2 (en) 2013-11-07
AU2017202610B9 (en) 2019-06-20
CA2871948C (en) 2020-09-08
AU2013256645A1 (en) 2014-11-13
SI2844292T1 (sl) 2020-02-28
CR20140488A (es) 2015-01-12
ECSP14025178A (es) 2015-08-31
TW201345923A (zh) 2013-11-16

Similar Documents

Publication Publication Date Title
PH12018501839A1 (en) St2l antagonists and methods of use
GB2527254B (en) Benzylisoquinoline alkaloids (BIA) Producing microbes, and methods of making and using the same
MY198562A (en) Antibodies specifically binding pd-1 and their uses
MX2012007710A (es) Alfa-amilasas.
PH12015501627A1 (en) Kv1.3 antagonists and methods of use
PH12014502601A1 (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
MX2019008211A (es) Estructuras fibrosas que comprenden particulas y metodos para fabricarlas.
PH12014501605A1 (en) Anti-lrp5 antibodies and methods of use
PH12016500598A1 (en) Protoxin-ii variants and methods of use
MX2017011223A (es) Variantes de protoxina ii y metodos de uso.
IN2014DN09798A (es)
MX2017012654A (es) Variantes de protoxina-ii y metodos de uso.
PH12016500826B1 (en) Anti-ccl17 antibodies
MX366815B (es) Polioles, su preparación y su uso.
MY184721A (en) Use of odiparcil in the treatment of a mucopolysaccharidosis
UA80618U (en) Use of n-steroylethanolamine as radiomodifier
IN2013CH00453A (es)